Back
ESC Premium Access

Questions and answers

Session: Spotlight on the effects of SGLT2 inhibition in heart failure (EBAC accredited)
Topic: Chronic Heart Failure, Other
Speaker: Professor F. Ruschitzka (Zurich, CH) Doctor M. Bonaca (Aurora, US) Professor S. Verma (Toronto, CA) Doctor M. Kosiborod (Kansas City, US)
Supported by an unrestricted educational grant from AstraZeneca
Event: ESC Congress 2019

Congress Presentation

Add to my library

Like

About the speakers

Professor Frank Ruschitzka

University Hospital Zurich, Zurich (Switzerland)
105 presentations
20 followers

Doctor Marc Bonaca

University of Colorado Anschutz Medical Campus, Aurora (United States of America)
32 presentations
1 follower

Professor Subodh Verma

St. Michael's Hospital, Toronto (Canada)
36 presentations
3 followers

Doctor Mikhail Kosiborod

St. Luke's Mid America Heart Institute, Kansas City (United States of America)
55 presentations
10 followers

4 more presentations in this session

The hidden burden of heart failure

Speaker: Professor F. Ruschitzka (Zurich, CH)

Access
Slides
Video
Like
Thumbnail

The clinical impact of SGLT2 inhibitor cardiovascular outcomes trials

Speaker: Doctor M. Bonaca (Aurora, US)

Access
Slides
Video
Like
Thumbnail

SGLT2 inhibitors: uncovering the mechanisms of cardiovascular risk reduction

Speaker: Professor S. Verma (Toronto, CA)

Access
Slides
Video
Like
Thumbnail

Lighting the way to the future of heart failure management

Speaker: Doctor M. Kosiborod (Kansas City, US)

Access
Slides
Video
Like
Thumbnail

Access the full session

Spotlight on the effects of SGLT2 inhibition in heart failure (EBAC accredited)

Speakers: Professor F. Ruschitzka, Doctor M. Bonaca, Professor S. Verma, Doctor M. Kosiborod, Professor F. Ruschitzka...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources